Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins - Wikidata - wikimedia - TriplyDB

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

http://www.wikidata.org/entity/Q34343020

about

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice Is there a role for plant-made vaccines in the prevention of HIV/AIDS?Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.The influence of delivery vectors on HIV vaccine efficacy A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)DNA vaccines against human immunodeficiency virus type 1 in the past decade.The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.Polyvalent AIDS vaccines.Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice.

P2860

Q28394899-D14C2968-BBF6-433E-99F0-4D4C5505476D Q28727249-502A1358-8251-484B-A94E-5EFA396F531F Q30350670-23D3872E-67E6-4939-AF02-8D94C6A4ECA5 Q30385999-1051A519-C4C1-4128-8A39-FA3365BCC6A8 Q33940220-0433882A-8620-4AB3-8133-F5DB393796F4 Q34077543-F2078679-A6FC-4B8E-B8A8-3BC5E157B544 Q34092753-7CECDB82-AEAC-4202-B4A5-008E96856ED0 Q34228558-1D4A3BD2-17FA-438D-9946-818DA9787A7A Q34344372-51A8730B-C7F3-4555-BF28-829F82C9E4A1 Q34434660-0A3C4FEB-28C0-4494-9418-6F30C1EE9FF8 Q34614953-EE8B6595-34B8-42D0-9F52-897E5F555947 Q34802680-E4DA6D20-5244-497D-9AF2-3B522AE497A0 Q35076961-3FAB920C-5E51-481A-8B86-D5FCD261ED51 Q35740733-2B7A70B2-7B01-4F45-A282-0F27764611C9 Q35745831-9E532704-88E9-46B1-AC32-29D3E8556E02 Q35867988-861EAE89-C389-4C93-B342-2A748F435BD1 Q35883032-83618DDA-AAE5-411C-B5C3-998AC4F179F6 Q36423935-29C1455D-3069-4C7B-9518-D45F8EEFABE2 Q36474235-D3008A4C-762F-431C-AA75-026B3C567936 Q36640081-2D41A786-C312-4E3F-9E44-89414490732E Q36672543-5C99DC6D-00C6-412D-9EB3-A03E778D6EBC Q36898706-7BDE3E54-E309-4F99-B84A-B09E0D9EB901 Q36933020-952ED90A-82F1-496C-8631-580861079ED8 Q36943971-9B26727C-0B58-4F70-9068-F9F90E30613B Q36972226-A778396E-EC49-4C64-9DD0-241323DE919A Q37094160-37294EDC-CDA4-4B5F-9944-C40554EDA07E Q37094429-09D12A4D-2CF1-4934-A327-6AD2D9C497D7 Q37107609-6263D46C-5B36-4FC0-9D25-9861CE3D33C1 Q37243886-BBA72C5A-8A59-4A91-B370-6483FDCE4E1A Q38363535-BF647717-0B06-48D4-8CD6-A889E394EA42 Q39756926-D1D5265A-0CE8-4733-93B2-68277AA67C81 Q41661161-12A994B9-AA6C-4938-9B5D-0217F60A5B2B Q54364542-A31C0FE6-3C6F-4ACD-BF8D-27869A6DC6DF

P2860

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

http://www.wikidata.org/entity/Q34343020

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@ast

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@en

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@nl

type

label

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@ast

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@en

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@nl

prefLabel

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@ast

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@en

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@nl

P1433

Q34343020-7462BC79-D22C-478D-BB0C-F5446EB6F4F1

P1476

Q34343020-D989EA5D-B6CD-4AF8-981F-CFEA48BD59D6

P2093

Q34343020-4FCC6839-484E-4309-9DB6-82E7DE1F83B2

Q34343020-5BC34479-C97D-4223-B3F0-8BC5DABADE50

Q34343020-94DD3FFD-337F-48E1-956C-B7CEEAE381F9

Q34343020-BD43E4FC-8967-42AB-954A-BAE513E82925

Q34343020-E6CBA23C-509C-4E71-978C-C67B6A857179

Q34343020-EBDBA6EA-4B3C-453C-BD34-952E53F643EB

P2860

Q34343020-00EAF418-C30C-43E6-A87A-B5C35152F2EE

Q34343020-02787399-2FF9-4060-AF2E-A741D530E3D4

Q34343020-040E2565-054B-467E-80C8-6CCB103BBED1

Q34343020-050819ED-0156-4CB1-97B6-B6DB70E7F2DE

Q34343020-0CFF32EE-0180-4560-B71B-10C1BA1D4113

Q34343020-113F86DE-02D4-492E-9262-C4C4913AC834

Q34343020-222CDF91-4C91-4A90-9F09-8757BA5A05C9

Q34343020-2580D71B-F1E3-414C-BAEF-B0B9F9442055

Q34343020-258792F4-175B-48C0-B269-C16CC4410659

Q34343020-29D2ABFC-95E9-4D62-861D-B2A18F2C7FC5

P304

Q34343020-1D81DB54-1866-4FB6-97C6-CE0BA08BEE71

P31

Q34343020-89E77EA0-8D9E-4AE5-B3F0-8A9138B88BBC

P356

Q34343020-AD915B69-86CE-4DA1-AC5E-330D45E4DA4E

P407

Q34343020-9A018028-3562-4740-8853-935CF01DDF9F

P433

Q34343020-72F54F17-844A-4D6F-9770-8EC3434FD79C

P478

Q34343020-0D8D0550-9182-41CD-9CDB-370C20B2D219

P577

Q34343020-D3B58BED-6E41-43B3-8CF1-65DA518F545E

P698

Q34343020-701E5A0D-F018-453A-9293-6EFC8C23FC25

P921

Q34343020-CFEAE8E8-5F9D-4DC4-A396-90E14B342E88

P932

Q34343020-3B3A85FC-2F29-4A0D-8A82-C96918A4F320

P356

JVI.76.15.7506-7517.2002

P1433

Journal of Virology

P1476

Robust recall and long-term me ...... us type 1 Gag and Env proteins

@en

P2093

Eric Pamer

http://www.w3.org/2001/XMLSchema#string

Ingrid Leiner

http://www.w3.org/2001/XMLSchema#string

John K Rose

http://www.w3.org/2001/XMLSchema#string

Karl Haglund

http://www.w3.org/2001/XMLSchema#string

Kristen Kerksiek

http://www.w3.org/2001/XMLSchema#string

Linda Buonocore

http://www.w3.org/2001/XMLSchema#string

P2860

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Attenuated vesicular stomatitis viruses as vaccine vectors

Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization

P304

7506-7517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.15.7506-7517.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12097563

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

136360

http://www.w3.org/2001/XMLSchema#string